从微胶质细胞-神经元相互作用看神经病理性疼痛:面向临床医生的转化综述
神经病理性疼痛影响高达10%的人群且常难治,本叙述性综述综合临床前与新兴人类数据,探讨微胶质细胞在疼痛启动、维持与缓解中的作用、性别差异及治疗意义。临床前证据表明微胶质细胞对疼痛启动必要且充分,男性以微胶质细胞机制为主而女性以T细胞通路为主,人类死后与胶质信号成像支持胶质参与但缺乏特定微胶质细胞靶点的直接验证。
要点
- 微胶质细胞通过CSF1-CSF1R等通路驱动疼痛启动,神经免疫干预宜早。
- 性别差异显著:男性以微胶质细胞机制为主,女性以T细胞通路为主。
- CSF1R-PET成像或有助于基于机制的患者选择,尚需前瞻性验证。
核心结论
- 微胶质细胞通过保守且可药物干预的通路协调疼痛启动与缓解。
- 神经免疫干预在早期最有效,因微胶质细胞更多驱动启动而非维持。
- 鉴于性别间微胶质细胞与T细胞机制不同,有必要开展性别分层试验设计。
- CSF1R-PET成像可能实现基于机制的患者选择,但需前瞻性临床验证。
研究设计与样本
- 叙述性综述,综合临床前与新兴人类数据(死后组织病理学、胶质信号PET成像、背根神经节转录组学)。
主要发现
- 临床前证据表明微胶质细胞对疼痛启动必要且充分。
- 神经损伤通过CSF1-CSF1R、嘌呤能受体、DAMP/Toll样受体信号、细胞因子级联(TNFα、IL-1β、IL-6)、前列腺素E₂、细胞外基质与突触重塑及BDNF-TrkB介导的去抑制参与中枢敏化。
- 微胶质细胞也通过促消退介质与STING/干扰素信号促进疼痛缓解。
- 性别差异显著:男性以微胶质细胞机制为主,女性以T细胞介导通路为主。
- 人类死后与胶质信号成像研究支持胶质参与慢性疼痛,但缺乏特定微胶质细胞靶点的直接验证。
临床怎么用
- 神经免疫干预应尽早考虑,因微胶质细胞更多驱动疼痛启动而非维持。
- 临床试验与治疗选择应考虑性别分层,因男女机制不同。
- CSF1R-PET成像有望用于基于机制的患者选择,但目前尚属研究性。
局限性
- 人类研究缺乏特定微胶质细胞靶点的直接验证。
- 转化意义需前瞻性临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/IMPORTANCE: Neuropathic pain affects up to 10% of the population and is often refractory to current treatments. Growing evidence implicates neuroimmune interactions, particularly microglia, in the pathophysiology, but their role is underappreciated in clinical practice. OBJECTIVE: To summarize current evidence for microglial contributions to neuropathic pain, emphasizing microglia-neuron interactions and translational implications for clinicians. EVIDENCE REVIEW: This narrative review synthesizes preclinical and emerging human data (postmortem histopathology, glial-signal positron emission tomography (PET) imaging, dorsal root ganglion transcriptomics) to examine microglial contributions to pain initiation, maintenance and resolution, sex differences and therapeutic implications. FINDINGS: Preclinical evidence demonstrates that microglia are necessary and sufficient for pain initiation. Nerve injury engages central sensitization through colony-stimulating factor 1 (CSF1)-CSF1 receptor (CSF1R), purinergic receptors, damage-associated molecular pattern/Toll-like receptor signaling, cytokine cascades (TNFα, IL-1β, IL-6), prostaglandin E₂, extracellular matrix and synaptic remodeling and brain-derived neurotrophic factor-tropomyosin receptor kinase B-mediated disinhibition. Microglia also contribute to pain resolution via pro-resolving mediators and stimulator of interferon genes (STING)/interferon signaling. Sex differences are prominent: microglial mechanisms predominate in males, whereas T-cell-mediated pathways prevail in females. Human postmortem and glial-signal imaging studies support glial involvement in chronic pain but lack direct validation of specific microglial targets. CONCLUSIONS: Microglia coordinate pain initiation and resolution via conserved, drug-addressable pathways. Three translational implications emerge: (1) neuroimmune interventions are most effective early, given that microglia drive initiation more than maintenance; (2) sex-stratified trial designs are warranted given divergent microglial versus T-cell mechanisms by sex and (3) CSF1R-PET imaging may enable mechanism-based patient selection. These implications require prospective clinical validation.
引用
- Zhang L, Yu J, Yu X, et al. Neuropathic pain through the perspective of microglia-neuron interactions: a translational review for clinicians. Reg Anesth Pain Med. 2026. PMID: 42419790. doi:10.1136/rapm-2026-107844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。